FDA label
What is Qelbree used for?
Qelbree contains viloxazine. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Qelbree?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Qelbree, capsule, extended release
Indications and Usage, quoted from the label by Supernus Pharmaceuticals, Inc (NDA211964). Cross-references to other label sections are left out.
Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
Source: DailyMed label, set id aedf408d-0f84-418d-9416-7c39ddb0d29a, version 16, effective October 5, 2026. NDC 17772-131, one of 3 listings for this product.
Questions
What is Qelbree used for?
The FDA label says: “Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.”
What drug class is Qelbree?
FDA lists viloxazine in the Norepinephrine Reuptake Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.